Abstract
BackgroundIntravenous belimumab (BEL) 10 mg/kg is approved in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE), on standard SLE therapy (SoC). A Phase III, double-blind (DB), study of subcutaneous...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have